<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253418</url>
  </required_header>
  <id_info>
    <org_study_id>NP-SH-009</org_study_id>
    <nct_id>NCT04253418</nct_id>
  </id_info>
  <brief_title>Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study</brief_title>
  <official_title>Prospective, Open Label, Multi-Center, Non-Significant Risk Study of Nano-Pulse Stimulation™ (NPS™ ) Technology in Healthy Adults With Sebaceous Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulse Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulse Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary study objective is to evaluate the optimization of Nano-Pulse Stimulation (NPS)&#xD;
      energy settings for lesion clearance of Sebaceous Hyperplasia (SH) lesions from facial areas&#xD;
      of healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Evaluate lesion clearance of treated facial Sebaceous Hyperplasia lesions using multiple&#xD;
           sized treatment tips with microneedles.&#xD;
&#xD;
        -  Evaluate lesion clearance of the treated Sebaceous Hyperplasia lesions using multiple&#xD;
           energy settings levels at various time points.&#xD;
&#xD;
        -  Evaluate skin effects and adverse event rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Anticipated">August 18, 2021</completion_date>
  <primary_completion_date type="Actual">August 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SH Lesion Clearance Rate</measure>
    <time_frame>60-days post-last NPS treatment</time_frame>
    <description>Clearance of SH lesions treated with NPS as rated by investigators.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Sebaceous Hyperplasia</condition>
  <condition>Skin Abnormalities</condition>
  <condition>Skin Lesion</condition>
  <arm_group>
    <arm_group_label>Nano-Pulse Stimulation (NPS) Treated Lesion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nano-Pulse Stimulation of target lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nano-Pulse Stimulation (NPS)</intervention_name>
    <description>Electrical pulses (nanosecond duration) applied directly to target SH lesions using sterile single-patient use treatment tips with microneedles.</description>
    <arm_group_label>Nano-Pulse Stimulation (NPS) Treated Lesion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female between 18 and 75 years of age&#xD;
&#xD;
          -  Voluntary, written informed consent to participate in this clinical investigation and&#xD;
             from whom consent has been obtained.&#xD;
&#xD;
          -  Understanding of the clinical investigation, agree to cooperate with the&#xD;
             investigational procedures and are willing to return for all the required follow-up&#xD;
             visits.&#xD;
&#xD;
          -  Understands that SHs are to be treated in a single treatment session is aware that&#xD;
             they may receive a second treatment at their third study visit&#xD;
&#xD;
          -  Must be able to visit clinic site at 7-, 30-, 60-days post-primary treatment of SH&#xD;
             lesion and at 30- and 60-days post-retreatment.&#xD;
&#xD;
          -  Clinically diagnosis of typical sebaceous hyperplasia.&#xD;
&#xD;
          -  Minimum of four SH lesions.&#xD;
&#xD;
          -  Undergo all study procedures including consent for photographs of the treated SH&#xD;
             sites.&#xD;
&#xD;
          -  Agrees to refrain from using all other SH lesion removal products or treatments&#xD;
             (topical medication including over-the-counter medications) during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Implantable electronic devices (i.e., pacemaker, implantable cardioverter&#xD;
             defibrillator)&#xD;
&#xD;
          -  Active infection or history of infection in designated test area within 90 days prior&#xD;
             to first treatment.&#xD;
&#xD;
          -  Not willing or able to sign the Informed Consent.&#xD;
&#xD;
          -  Known to be immune-compromised.&#xD;
&#xD;
          -  Known to be a keloid producer.&#xD;
&#xD;
          -  Taking blood thinning medications.&#xD;
&#xD;
          -  Insulin dependent, Type I diabetics.&#xD;
&#xD;
          -  Allergies to Lidocaine or Lidocaine-like products.&#xD;
&#xD;
          -  Employed by the sponsor, clinic site, or entity associated with the conduct of the&#xD;
             study.&#xD;
&#xD;
          -  Have any condition or situation which, in the Investigator's opinion, puts the subject&#xD;
             at significant risk, could confound the study results, or may interfere significantly&#xD;
             with the subject's participation in the study.&#xD;
&#xD;
          -  Known prior inability to complete required study visits during treatment period.&#xD;
&#xD;
          -  Use of any other investigational drug, therapy, or device within the past 30 days of&#xD;
             enrollment or concurrent participation in another research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Nuccitelli, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Pulse Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clear Dermatology &amp; Aesthetics Center / InvestigateMD</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser and Skin Surgery Center of Northern California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AVA MD</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Laser &amp; Skin Care</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Skin Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Abnormalities</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

